4d Pharma PLC - 4D hosts virtual R&D event
4D pharma plc
(the "Company" or "4D")
4D pharma hosts R&D webinar providing an overview of world leading Live Biotherapeutic discovery platform, MicroRx®
The event is introduced by Dr.
· Why 4D's focus on the mechanism of single-strain LBPs drives a rational drug discovery approach and guides effective development
· How the MicroRx platform investigates functionality
· The drug discovery process and considerations for the microbiome
· 4D's proprietary culture collection
· Neurodegenerative diseases and 4D pharma candidates - MRx0029 and MRx0005
· MRx0518, oncology and the MicroRx platform
The presentation slides and recording of the event are accessible via the "Reports and Presentations" area of 4D's website at www.4dpharmaplc.com/en/investors/reports-presentations.
The microbiome is a novel area of medicine with profound impacts on human health and disease. 4D pharma recently announced proof of concept data for their lead immuno-oncology candidate MRx0518 in combination with Keytruda, highlighting that the 42% disease control rate observed in Part A of the study, far exceeded the predefined 10% threshold for expansion. This, in addition with 4D pharma holding the largest IP portfolio and working in diverse therapy areas, has driven increased interest in the Company's science and development from a range of stakeholders.
An insightful Q&A session follows the presentation involving analysts from Chardan, N+1
4D's Live Biotherapeutic Products are orally delivered single strains of bacteria that are naturally found in the healthy human gut. The Company has six clinical studies in progress, namely a Phase II clinical study of BLAUTIX(R) in Irritable Bowel Syndrome (IBS), a Phase I/II study of MRx0518 in combination with KEYTRUDA (pembrolizumab) in solid tumours, a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumours, a Phase I study of MRx0518 in patients with pancreatic cancer, a Phase I/II study of MRx-4DP0004 in asthma, and a Phase II study of MRx-4DP0004 in patients hospitalised with COVID-19. Preclinical-stage programs include candidates for CNS disease such as Parkinson's disease and other neurodegenerative conditions. The Company has a research collaboration with MSD, a tradename of Merck & Co., Inc.,
For more information, refer to https://www.4dpharmaplc.com.
Investor Relations email@example.com
N+1 Singer - Nominated Adviser and Joint Broker +44 (0)20 7496 3000
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the
Quick facts: 4D pharma plc
Market Cap: £122.46 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE